Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://innovativemedicine.jnj.com/emea/
Bristol Myers Squibb
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are motivated by the power of science, with a legacy of pursuing bold science across oncology, hematology, cardiovascular, immunology and neuroscience. We’re accelerating the development of new medicines with differentiated research platforms and leading technology to define what’s possible for the future of medicine and the patients we serve.
https://www.globalbmsmedinfo.com/
© 2026 Bristol-Myers Squibb Company
Gilead | Kite
Gilead and Kite Oncology are creating the future of oncology. From ADCs and small molecules to cell therapy, our R&D programs and partnerships are focused on helping to bring more life to people with cancer and changing the way cancer is treated.
Cell Therapy Hub link: CellTherapyHub.com
Regeneron
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center. Visit www.Regeneron.com to learn more.
Adaptive Biotechnologies
Adaptive Biotechnologies is a leader in the field of immunosequencing, transforming the understanding of the immune system through cutting-edge technologies.
clonoSEQ® is a next-generation sequencing (NGS) test that enables precise and sensitive measurement of minimal residual disease (MRD) in blood cancers, such as leukemia and lymphoma. This test provides clinicians with valuable insights into disease monitoring, relapse detection, and treatment response. Now available in Europe, clonoSEQ empowers healthcare providers with advanced tools for better patient outcomes in the fight against hematologic malignancies.
Adaptive Biotechnologies
1165 Eastlake Ave E, Seattle WA 98109 USA
www.adaptivebiotech.com
[email protected]
Amgen
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.
Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
Amgen
One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
Tel: +1 805-447-1000
www.amgen.com (can refer to “contact us” on this website for different email contacts)
